Industry Update: Biotechnology

IBiotech industry updatendustry Highlights

  • On October 20, 2022, AbbVie completed the acquisition of DJS Antibodies Ltd for $255 million. DJS is focused on difficult-to-drug disease-causing proteins, such as G protein-coupled receptors (GPCRs), and compliments AbbVie’s efforts to focus on specific transmembrane protein targets.
  • On September 8, 2022, Autobahn Therapeutics, a biotechnology company focused on restoring hope for people affected by CNS disorders, announced the closing of a $32.7 million financing round. Current shareholders ARCH Venture Partners, Cowen Healthcare Investments, BVF Partners L.P., Biogen, Bristol Myers Squibb, Pfizer Ventures, Invus, Section 32, Samsara BioCapital, Alexandria Venture Investments and GT Healthcare all participated in the round.

Past Industry Updates

Biotechnology: August 2022

Biotechnology: April 2022

Biotechnology: February 2022

Biotechnology: October 2021

Biotechnology: July 2021

Biotechnology: May 2021

Biotechnology: January 2021

Biotechnology: October 2020

Biotechnology: July 2020

Biotechnology: May 2020

Biotechnology: December 2019

Biotechnology: October 2019

More Industry Reports